At 10 days after the injection of DLBCL cells, half of the mice derived from both the PDK4 OE group and EV group were treated with rituximab (12.5 mg/kg) injected intraperitoneally daily for 2 weeks. The gene discussed is PDK4; the disease is diffuse large B-cell lymphoma.